Acquired CYP19A1 amplification is an early specific mechanism of aromatase inhibitor resistance in ERα metastatic breast cancer

Tumor evolution is shaped by many variables, potentially involving external selective pressures induced by therapies1. After surgery, estrogen receptor (ERα) positive breast cancer (BCa) patients are treated with adjuvant endocrine therapy2 including selective estrogen receptor modulators (SERMs) an...

Descripción completa

Detalles Bibliográficos
Autores principales: Magnani, Luca, Frige, Gianmaria, Gadaleta, Raffaella Maria, Corleone, Giacomo, Fabris, Sonia, Kempe, Mannus H., Vershure, Pernette J., Barozzi, Iros, Vircillo, Valentina, Hong, Sung-Pil, Perone, Ylenia, Saini, Massimo, Trumpp, Andreas, Viale, Giuseppe, Neri, Antonino, Ali, Simak, Colleoni, Marco Angelo, Pruneri, Giancarlo, Minucci, Saverio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5326683/
https://www.ncbi.nlm.nih.gov/pubmed/28112739
http://dx.doi.org/10.1038/ng.3773

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5326683/
https://www.ncbi.nlm.nih.gov/pubmed/28112739
http://dx.doi.org/10.1038/ng.3773

Ejemplares similares